Angiotensin, inflammation, hypertension, and cardiovascular disease

Current Hypertension Reports

Volumn 3, Issue 1, 2001, Pages 61-67

  Luft, Friedrich C ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASOCONSTRICTOR AGENT;

CARDIOVASCULAR DISEASE; GENETICS; HUMAN; HYPERTENSION; IMMUNOLOGY; INFLAMMATION; REVIEW;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; INFLAMMATION; NF-KAPPA B; VASOCONSTRICTOR AGENTS;

EID: 0035259602     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0082-y     Document Type: Article

References (53)

1. Alexander RW: Theodore Cooper Memorial Lecture: Hypertension and the pathogenesis of atherosclerosis, oxidative stress, and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995, 25: 155-161.
2. Nakazono K, Watanabe N, Matsuno K, et al: Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A 1991, 88: 10045-10048.
3. Irani K: Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000, 87: 179-183.
4. Baichwal VR, Baeuerle PA: Activate NF kB or die? Curr Biol 1997, 7: R94-R96.
5. Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide regulated kinases: kinase activation by phosphoinositide dependent phosphorylation. Annu Rev Biochem 1999, 68: 965-1014.
6. Data SR, Brunet A, Greenberg ME: Cellular survival: a play in three akts. Genes Dev 1999, 13: 2905-2927.
7. Griendling K, Masuko UF: NADH/NADPH oxidase and vascular function. Trends Cardiovasc Med 1997, 7: 301-307.
8. Fukuhara M, Geary RL, Diz DI, et al: Angiotensin convering enzyme expression in human carotid artery atherosclerosis. Hypertension 2000, 35: 353-359.
9. Touyz RM, Schiffrin EL: Ang II stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 1999, 34: 976-982.
10. Viedt C, Soto U, Krieger-Brauer HI, et al: Differential activation of mitogen activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000, 20: 940-948.
11. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, et al: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor kappa B activation and monocyte chemoattractant protein 1 synthesis. J Immunol 1998, 161: 430-439.
12. Barnes PJ, Karin M: Nuclear factor kB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336: 1066-1078.
13. Intengan HD, Schiffrin EL: Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000, 36: 312-318.
14. Brasier AR, Ron D, Tate JE, et al: A family of constitutive C/EBP like DNA binding proteins attenuate the IL-1 alpha induced, NF kappa B mediated trans activation of the angiotensinogen gene acute phase response element. EMBO J 1990, 9: 3933-3944.
15. Brasier AR, Li J, Copland A: Transcription factors modulating angiotensinogen gene expression in hepatocytes. Kidney Int 1994, 46: 1564-1566.
16. Brasier AR, Li J, Wimbish KA: Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996, 27: 1009-1017.
17. Jamaluddin M, Meng T, Sun J, et al.: Angiotensin II induces nuclear factor (NF) kappaB1 isoforms to bind the angiotensinogen gene acute phase response element: a stimulus specific pathway for NF kappaB activation. Mol Endocrinol 2000, 14: 99-113.
18. Hernandez-Presa M, Bustos C, Ortego M, et al: Angiotensin converting enzyme inhibition prevents arterial nuclear factor kappa B activation, monocyte chemoattractant protein 1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997, 95: 1532-1541.
19. Hernandez-Presa MA, Bustos C, Ortego M, et al: ACE inhibitor quinapril reduces the arterial expression of NF kappaB dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153: 1825-1837.
20. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin converting enzyme inhibitor, ramipril on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. N Engl J Med 2000, 342: 145-153.
21. Morrissey JJ, Klahr S: Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 1997, 52: 926-933.
22. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III increases MCP 1 and activates NF kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 2000, 57: 2285-2298.
23. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, et al: Angiotensin II activates nuclear transcription factor kappaB through AT (1) and AT (2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000, 86: 1266-1272.
24. Bush E, Maeda N, Kuziel WA, et al: CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II induced hypertension. Hypertension 2000, 36: 360-363.
25. Day FL, Rafty LA, Chesterman CN, et al: Angiotensin II (ATII) inducible platelet derived growth factor A chain gene expression is p42/44 extracellular signal regulated kinase 1/2 and Egr 1 dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. J Biol Chem 1999, 274: 23726-23733.
26. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101: 1372-1378.
27. Han Y, Runge MS, Brasier ARL: Angiotensin II induces interleukin 6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor kappa B transcription factors. Circ Res 1999, 84: 695-703.
28. Kranzhofer R, Schmidt J, Pfeiffer CA, et al: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19: 1623-1629.
29. Pueyo ME, Gonzalez W, Nicoletti A, et al: Angiotensin II stimulates endothelial vascular cell adhesion molecule 1 via nuclear factor kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000, 20: 645-651.
30. Kitamoto S, Egashira K, Kataoka C, et al: Increased activity of nuclear factor kB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation 2000, 102: 806-812.
31. Tharaux PL, Chatziantoniou C, Fakhouri F, et al: Angiotensin II activates collagen I gene through a mechanism involving MAP/ER kinase pathway. Hypertension 2000, 36: 330-336.
32. Bohlender J, Fukamizu A, Lippoldt A, et al: High human renin hypertension in transgenic rats. Hypertension 1997, 29: 428-434.
33. Luft FC, Mervaala EMA, Müller DN, et al.: Hypertensioninduced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999, 33: 212-218.
34. Mervaala EMA, Müller D, Park J-K, et al.: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33: 389-395.
35. Müller DN, Dechend R, Mervaala EMA, et al.: NFkB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000, 35: 193-201.
36. Mervaala EMA, Müller DN, Park J-K, et al.: Cyclosporine A protects against angiotensin II-induced end-organ damage in double transgenic rats with human renin and angiotensinogen genes. Hypertension 2000, 35: 360-366.
37. Mervaala E, Müller DN, Schmidt F, et al.: Angiotensin II induces blood pressure-independent inflammation and cell proliferation in high human renin hypertension. Hypertension 2000, 35: 587-594.
38. Müller D, Mervaala EMA, Dechend R, et al.: AT1 rec ep tor blockade reduces tissue factor via inhibition of NF-kB and AP-1 in angiotensin II-induced cardiac damage. Am J Pathol 2000, 157: 111-122.
39. Müller DN, Mervaala EMA, Schmidt F, et al.: Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000 36: 282-290.
40. Faggiotto A, Paoletti R. State-of-the-art lecture. Statins and blockers of the renin-angiotensin-system: vascular protection beyond their primary mode of action. Hypertension 1999, 34: 987-996.
41. Kreuzer J, Watson L, Herdegen T, et al.: Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II-mediated signal transduction: suppression of c-Jun. and c-Fos in vascular smooth muscle cells in vitro. Eur J Med Res 1999, 4: 135-143.
42. Luo JD, Zhang WW, Zhang GP, et al.: Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999, 11: 903-908.
43. Nickenig G, Baumer AT, Temur Y, et al.: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100: 2131-2134.
44. Park JK, Müller DN, Mervaala EMA, et al.: Cerivastatin prevents leukocyte infiltration and iNOS induction by inhibition of ERK phosphorylation and NF-kB activation in angiotensin II-induced end-organ damage. Kidney Int 2000, 58: 1420-1430.
45. Ortego M, Bustos C, Hernandez-Presa MA, et al.: Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells. Atherosclerosis 1999, 147: 253-261.
46. Magee T, Marshall C: New insights into the interaction of Ras with the plasma membrane. Cell 1999, 98: 9-12.
47. Ikeda U, Shimpo M, Ohki R, et al.: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000, 36: 325-329.
48. Nataraj C, Oliverio MI, Mannon RB, et al.: Angiotensin II regulates cellular immune responses through a calcineurindependent pathway. J Clin Invest 1999, 104: 1693-1701.
49. Azizi M, Rousseau A, Ezan E, et al.: Acute angiotensinconverting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyllysyl-proline. J Clin Invest 1996, 97: 839-844.
50. Azizi M, Ezan E, Nicolet L, et al.: High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin converting enzyme inhibition. Hypertension 1997, 30: 1015-1019.
51. Boulanger CM, Ezan E, Masse F, et al.: The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aorta. Eur J Pharmcol 1998, 363: 153-156.
52. Baumann H, Wang Y, Richards CD, et al.: Endotoxin-induced renal inflammatory response. Oncostatin M as a major mediator of suppressed renin expression. J Biol Chem 2000, 275: 22014-22019.
53. Berk BC: Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tryrosine kinases. J Am Soc Nephrol 1999, 1 1: S62-S68.